During the health care debate, this website focused on the biologics provisions in the law. Because of the influence of biotechnology companies, lawmakers pushed for an exemption of 12 years for the expensive drugs, during which time no generics could enter the market. In the final negotiations that got lowered to 10 years. In some [...]
Biologic Market Slips as Biosimilars Come to the Fore |
| By: David Dayen Tuesday December 20, 2011 8:55 am |



1 Comment

Support this site!
Subscribe to the newsletter
Advertise on Firedoglake
Send
us your tips
Make us your homepage
About FDL News Desk